New Options for the Management of Castration-Resistant Prostate Cancer: A Case Perspective

作者：Goetz Dawn^*

来源：Journal of the National Comprehensive Cancer Network, 2011, 9(Suppl_3): S13-S24.

DOI：10.6004/jnccn.2011.0128

• Prostate cancer
• castration-resistant
• hormone-refractory
• chemotherapy
• hormone therapy
• abiraterone acetate
• docetaxel
• immunotherapy
• sipuleucel-T
• cabazitaxel

Prostate cancer is the leading cause of cancer and second leading cause of death among men. Management of localized disease is fairly straight-forward, but treatment for locally advanced or metastatic disease is much less so. Androgen-deprivation therapy serves as the foundation of treatment for patients with locally advanced or metastatic disease. Although most patients with prostate cancer show a response to medical or surgical castration, many eventually experience a hormone-refractory, incurable state. Until recently, therapeutic options for CRPC have been limited and focused on systemic chemotherapeutic options. Unfortunately, however, this provides a minimal increase in overall survival, at the cost of significant additional toxicities. Therefore, much research has gone into developing other suitable therapies with potentially less toxicity. This article uses a case study approach to discuss new options for the treatment of castration-resistant prostate cancer. (JNCCN 2011;9[Suppl 3]:S13-524)

• 出版日期2011-2